| 商品名称 | Comirnaty |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | COVID-19 virus infection |
|---|
| 通用名/非专利名称 | tozinameran, riltozinameran and tozinameran, famtozinameran and tozinameran, COVID-19 mRNA Vaccine (nucleoside modified) |
|---|
| 活性成分 | Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 |
|---|
| 产品号 | EMEA/H/C/005735 |
|---|
| 患者安全信息 | yes |
|---|
| 授权状态 | Authorised |
|---|
| ATC编码 | J07BN01 |
|---|
| 是否额外监管 | yes |
|---|
| 是否仿制药 | no |
|---|
| 是否生物类似药 | no |
|---|
| 是否附条件批准 | no |
|---|
| 是否特殊情形 | no |
|---|
| 是否加速审评 | no |
|---|
| 是否罕用药 | no |
|---|
| 批准上市日期 | 2020/12/21 |
|---|
| 上市许可持有人/公司名称 | BioNTech Manufacturing GmbH |
|---|
| 人用药物治疗分组 | Vaccines |
|---|
| 审评意见发布日期 | 2020/12/21 |
|---|
| 决定日期 | 2023/10/19 |
|---|
| 修订号 | 45 |
|---|
| 适应症 | Comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Original/Omicron BA.1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.The use of this vaccine should be in accordance with official recommendations. |
|---|
| 首次发布日期 | 2020/12/23 |
|---|
| 修订日期 | 2023/10/31 |
|---|
| 产品信息 | https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty |
|---|